Abstract
Back to table of contents Previous article Next article Letter to the EditorFull AccessDr. Sallee and Colleagues ReplyFLOYD R. SALLEE, M.D., PH.D., GOPALAN SETHURAMAN, PH.D., LAUREN E. SINE, M.S., and HONG LIU, M.D., FLOYD R. SALLEESearch for more papers by this author, M.D., PH.D., GOPALAN SETHURAMANSearch for more papers by this author, PH.D., LAUREN E. SINESearch for more papers by this author, M.S., and HONG LIUSearch for more papers by this author, M.D., Cincinnati, OhioPublished Online:1 Aug 2001https://doi.org/10.1176/appi.ajp.158.8.1340-aAboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: The letter of Drs. Watson and Young relates to two methodological issues: the use of multiple baselines to more accurately measure baseline levels of neurohormones (e.g., cortisol) and the use of cortisol concentrations in particular as a covariate in the analysis of growth hormone release.To clarify, we measured cortisol at two time points before administration of yohimbine. In effect, we had two baseline values for cortisol and growth hormone but chose the value at 30 minutes before administration as the reference baseline. The statistical validity of using one value as the baseline instead of averaging a number of values lies in the fact that an estimate based on averages from the same subjects decreases the within-subject correlation coefficient. This affects the repeated measures analysis of variance that is derived from the premise that within-subjects correlation is greater than between-subjects correlation.The mean cortisol concentration at –30 minutes was 9.1 μg/ml (SD=8.4) for the anxious subjects and 6.5 μg/ml (SD=2.8) for the comparison subjects and was reported as such in the baseline results of the article. The cortisol levels at time 0 (immediately before administration of yohimbine) were 8.0 μg/ml (SD=6.7) for the anxious subjects and 6.8 μg/ml (SD=3.2) for the comparison subjects. The average of the two baseline values for all subjects yielded a baseline of 8.5 μg/ml (SD=7.4) for the anxious subjects and 6.7 μg/ml (SD=2.4) for the comparison subjects. The two groups did not differ on either baseline cortisol measure.As Drs. Watson and Young suggest, we measured the correlations between cortisol and growth hormone concentrations at –30, 0, 60, 90, and 120 min; the correlation coefficients (ρ) were, respectively, –0.04, –0.21, 0.45, 0.37, and –0.20 for the anxious group and 0.50, 0.14, –0.70, –0.50, and –0.30 for the comparison group. The correlation values are modest; none approach statistical significance. Thus, the use of cortisol as a covariate does not appear to enhance the model.To reiterate, this was a small study. Our hypotheses were formed to evaluate the effect of yohimbine on hormonal output, including cortisol and growth hormone. We agree that under most circumstances corticosteroids have the potential for interaction with growth hormone output from the pituitary but apparently not under the conditions or the population addressed by this study. FiguresReferencesCited byDetailsCited ByNone Volume 158Issue 8 August 2001Pages 1340-a-1340 Metrics History Published online 1 August 2001 Published in print 1 August 2001
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.